Comparison of patient-controlled caudal epidural analgesia and patient-controlled intravenous analgesia after perianal surgery:

A prospective randomized study

Le Xu M.M.1*, Pei Zhang, M.M.1*, Wei Long, M.M.1, Rurong Wang, M.D.1 Xuehan Li, M.D.‡

Affiliations

1.Deptartment of Anesthesiology, and Laboratory of Anesthesia and Intensive Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, China

* These authors contributed equally to this work.

‡Corresponding author: Xuehan Li, PhD., M.D., Department of Anesthesiology, and Laboratory of Anesthesia and Intensive Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, China (E-mail: XuehanLi@scu.edu.cn), Phone number: +86-18980605253.
CERTIFICATE OF ENGLISH EDITING

This is to certify that the manuscript entitled

**Comparison of patient-controlled caudal epidural analgesia and patient-controlled intravenous analgesia after perianal surgery: A prospective randomized study**

By: Rurong Wang, Le Xu, Wei Long, Pei Zhang, Xuehan Li.

commissioned to us has been carefully edited by a native English-speaking editor at Sagesci. The grammar, spelling, and punctuation of the text have carefully been checked and corrected wherever required. We believe that the language of this paper has been considerably improved to meet academic standards. You may please contact us for further queries regarding the editing process.

Date of issue
April 8, 2022

Disclaimer: The changes in the document may be accepted or rejected by the authors at their sole discretion after our editing. Therefore, Sagesci would not be responsible for the revisions made to this document after our editing carried on April 8, 2022

Sagesci
Website: [www.sagesci.cn](http://www.sagesci.cn)
2000+ native English editors: [www.sagesci.cn](http://www.sagesci.cn)
| Section/Topic       | Item No | Checklist item                                                                                                                                                                                                 | Reported on page No |
|--------------------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| **Title and abstract** |         |                                                                                                                                                                                                            |                     |
|                    | 1a      | Identification as a randomised trial in the title                                                                                                                                                    | 1                   |
|                    | 1b      | Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)                                                                                 | 2-3                 |
| **Introduction**   |         |                                                                                                                                                                                                            |                     |
| Background and objectives | 2a      | Scientific background and explanation of rationale                                                                                                                                                    | 4                   |
|                    | 2b      | Specific objectives or hypotheses                                                                                                                                                                       | 5                   |
| **Methods**        |         |                                                                                                                                                                                                            |                     |
| Trial design       | 3a      | Description of trial design (such as parallel, factorial) including allocation ratio                                                                                                                      | 5                   |
|                    | 3b      | Important changes to methods after trial commencement (such as eligibility criteria), with reasons                                                                                                     | No                  |
| Participants       | 4a      | Eligibility criteria for participants                                                                                                                                                                    | 5                   |
|                    | 4b      | Settings and locations where the data were collected                                                                                                                                                    | 5                   |
| Interventions      | 5       | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered                                                             | 6-8                 |
| Outcomes           | 6a      | Completely defined pre-specified primary and secondary outcome measures, including how and when they were actually assessed                                                                              | 8                   |
|                    | 6b      | Any changes to trial outcomes after the trial commenced, with reasons                                                                                                                                   | No                  |
| Sample size        | 7a      | How sample size was determined                                                                                                                                                                          | 8                   |
|                    | 7b      | When applicable, explanation of any interim analyses and stopping guidelines                                                                                                                              | No                  |
| Randomisation:     |         |                                                                                                                                                                                                            |                     |
| Sequence generation| 8a      | Method used to generate the random allocation sequence                                                                                                                                                  | 6                   |
|                    | 8b      | Type of randomisation; details of any restriction (such as blocking and block size)                                                                                                                      | 6                   |
| Allocation         | 9       | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned                                      | 6                   |
| Concealment        |         |                                                                                                                                                                                                            |                     |
| Implementation     | 10      | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions                                                                               | 6                   |
| Blinding           | 11a     | If done, who was blinded after assignment to interventions (for example, participants, care providers, those                                                                                           | No                  |
| Number | Item                                                                 | Description                                                                                                                                                                                                 |
|--------|----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11b    | Statistical methods                                                 | If relevant, description of the similarity of interventions                                                                                                                                            |
| 12a    | Statistical methods                                                  | Statistical methods used to compare groups for primary and secondary outcomes                                                                                                                          |
| 12b    | Statistical methods                                                  | Methods for additional analyses, such as subgroup analyses and adjusted analyses                                                                                                                        |
| 13a    | Participant flow                                                     | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome                                                             |
| 13b    | Participant flow                                                     | For each group, losses and exclusions after randomisation, together with reasons                                                                                                                          |
| 14a    | Recruitment                                                          | Dates defining the periods of recruitment and follow-up                                                                                                                                                 |
| 14b    | Recruitment                                                          | Why the trial ended or was stopped                                                                                                                                                                       |
| 15     | Baseline data                                                       | A table showing baseline demographic and clinical characteristics for each group                                                                                                                                 |
| 16     | Numbers analysed                                                    | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups                                                                       |
| 17a    | Outcomes and estimation                                              | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)                                                          |
| 17b    | Outcomes and estimation                                              | For binary outcomes, presentation of both absolute and relative effect sizes is recommended                                                                                                                 |
| 18     | Ancillary analyses                                                   | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory                                                                   |
| 19     | Harms                                                                | All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)                                                                                            |
| 20     | Discussion                                                           | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses                                                                                         |
| 21     | Generalisability                                                    | Generalisability (external validity, applicability) of the trial findings                                                                                                                                  |
| 22     | Interpretation                                                      | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence                                                                                         |
| 23     | Other information                                                   | Registration number and name of trial registry                                                                                                |
| 24     | Other information                                                   | Where the full trial protocol can be accessed, if available                                                                                                                                            |
| 25     | Other information                                                   | Sources of funding and other support (such as supply of drugs), role of funders                                                                                                                        |

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.
成都上锦南府医院医学伦理委员会审查批件

2019年 审 (2019042504) 号

| 科室（专业）：麻醉科 | 项目负责人姓名及职称：王儒蓉 教授 |
|----------------------|-------------------------------------|
| 项目名称            | 腹腔镜术后自控腹管镇痛用于肛周手术后镇痛的可行性和安全性 |
| 研究方案            | 项目编号：-                              |
| 知情同意书          | 版本号：-                                 |
| 专家评议批准日期：2019.04.25 | 版本日期：-                               |

审查意见：
1. 研究者资质符合伦理要求。
2. 研究方案及知情同意书基本符合伦理要求。

审查结果：☑同意  □作必要修正后同意  □作必要修正后再审  □不同意  □终止或暂停

请遵循我国相关法律、法规和规章（SFDA《药物临床试验质量管理规范》（2003）、《医疗器械临床试验规定》（2004）、WMA《赫尔辛基宣言》和CIOMS《人体生物医学研究国际道德指南》、卫生部《涉及人的生物医学研究伦理审查办法（试行）（2007）》），遵循医学伦理委员会批准的方案和知情同意书开展临床试验（研究），保护受试者的健康与权利。

在试验（研究）过程中，若变更主要研究者，对临床研究方案、知情同意书等的任何修改，请申请人提交修正案审查申请。

发生严重不良事件，请申请人及时提交严重不良事件报告；紧急报告之后，尽快提交详细的严重不良事件随访报告。

请递交年度和定期跟踪审查报告；当出现任何可能显著影响试验（研究）进行或增加受试者危险的情况时，请申请人及时向医学伦理委员会提交书面报告。

试验（研究）纳入了不符合纳入标准或排除标准的受试者，符合中止试验（研究）规定而未让受试者退出试验（研究），给予错误治疗或剂量，给予方案禁止的合并用药等没有遵从方案开展研究的情况；或可能对受试者的权益/健康、以及研究的科学性造成不良影响等违背伦理原则与规范的情况，请申办者/监查员/研究者提交违背方案报告。

申请人暂停或提前终止临床试验（研究），请及时提交暂停/终止试验（研究）报告。

完成临床试验（研究），请申请人提交结题报告。

项目伦理审查未获同意（批件）的，严禁开展项目临床研究。

单位（章）：

主任委员（签名）：

2019年 4 月 25 日
Chengdu Shangjin Nanfu Hospital Medical Ethics Committee
review and approval

| Department (specialty): | Anesthesiology department | Name and title of project leader: Professor Rurong Wang |
|------------------------|---------------------------|---------------------------------------------------|
| Project name:          | The feasibility and safety of patient-controlled caudal epidural analgesia in the patient after perianal surgery | |
| Research protocol      | -                         | Date of approval for expert review: 2019.04.25 |
| Informed consent form | -                         | -                                                 |

Review opinions:
1. The qualifications of researchers meet the ethical requirements.
2. The research plan and informed consent basically meet the ethical requirements.

Review results: ☑ Agree ☐ Agree after making changes ☐ Re-review after making changes.
☐ Disagree ☐ Termination or suspension

Please follow the relevant laws, regulations and regulations of China (SFDA "Quality Management Practice for Drug Clinical Trials" (2003), "Regulations for Medical Device Clinical Trials" (2004), WMA "Declaration of Helsinki" and CIOMS The International Ethical Guidelines for Biomedical Research on Human beings and the Guidelines for ethical Review of Biomedical Research involving Human beings (Trial) of the Ministry of Health (2007), follow the protocol approved by the Medical Ethics Committee and informed consent to conduct clinical trials (studies) to protect the health and rights of subjects.

In the course of the trial (study), if the principal investigator is changed, any modification to the clinical study protocol, informed consent, etc., the applicant shall submit the application for amendment review.

If a serious adverse event occurs, the applicant should submit a serious adverse event report in time; Detailed follow-up reports of serious adverse events should be submitted as soon as possible after the emergency report.

Please submit annual and periodic follow-up review reports; Applicants are requested to submit a written report to the Medical Ethics Committee in a timely manner in the event of any condition that may significantly affect the conduct of the study or increase the risk to the subject.

If the study did not comply with the protocol by including subjects who did not meet the inclusion criteria or the exclusion criteria, failing to withdraw subjects from the study in accordance with the suspension criteria, giving wrong treatment or dose, giving drug combinations prohibited by the protocol, etc.; Or the violation of ethical principles and norms, which may have adverse effects on the rights and interests/health of the subjects, as well as the scientific nature of the study, the reports shall be submitted by the sponsor/supervisor/researcher.

If the applicant suspends or terminates the clinical trial (study) in advance, please submit the suspension/termination report in a timely manner. If complete the clinical trial (study), please submit the final report.

If the ethical review of the project is not approved (approval document), the clinical study of the project is strictly prohibited.

Unit (Chapter)
Chairman (Signed)
April 25, 2019
| Date   | Name | Anesthesia | Type | Gender | Age | Height | Weight | BMI | Education | Anesthetic effect | Anesthesia duration | Postoperative catheter removal time | Postoperative catheter dressing change | Complications of anesthesia | Duration of surgery | VAS(2h) | VAS(4h) | VAS(6h) | VAS(12h) | VAS(24h) | VAS(72h) | VAS(first 12h) | Phrenic nerve block (tablet) |
|--------|------|------------|------|--------|-----|--------|--------|-----|-----------|------------------|----------------------|-------------------------------|---------------------------------|------------------------|-------------------|-----------|--------|--------|--------|--------|--------|-----------|---------------------|
| 04.26  | 1    | PCA        | M    | Male   | 55  | 156    | 69     | 25.03 | Excellent | school           | surgery              | 15               | 0                  | 0                  | 0                  | 0                  | 0                  | 0                  | 0                  | 0                  |
| 04.26  | 2    | CBR        | M    | Male   | 54  | 140    | 47     | 18.94 | Excellent | surgery              | surgery              | 45               | 0                  | 0                  | 0                  | 1                  | 2                  | 2                  | 1                  | 4                  | 4                  | 0                  |
| 04.26  | 3    | CBR        | M    | Male   | 58  | 145    | 80     | 21.29 | degree    | surgery              | surgery              | 17               | 4                  | 7                  | 2                  | 3                  | 2                  | 1                  | 6                  | 5                  | 3                  | 0                  |
| 04.26  | 4    | CBR        | F    | Female | 48  | 195    | 95     | 22.81 | Excellent | Junior high      |                      | 23               | 0                  | 0                  | 0                  | 3                  | 2                  | 2                  | 2                  | 4                  | 3                  | 8                  |
| 05.27  | 1    | CBR        | F    | Female | 61  | 183    | 73     | 27.47 | Excellent | school           | surgery              | 18               | 0                  | 0                  | 0                  | 2                  | 4                  | 4                  | 2                  | 2                  | 6                  | 6                  |
| 05.27  | 2    | CBR        | F    | Female | 48  | 197    | 95     | 22.13 | degree    | surgery              | surgery              | 15               | 0                  | 0                  | 0                  | 2                  | 4                  | 5                  | 3                  | 6                  | 6                  | 3                  |
| 05.27  | 3    | CBR        | F    | Female | 25  | 170    | 78     | 28.99 | Excellent | Higher school    |                      | 23               | 0                  | 0                  | 0                  | 2                  | 2                  | 3                  | 5                  | 2                  | 1                  | 3                  |
| 05.28  | 1    | CBR        | F    | Female | 50  | 145    | 46     | 18.40 | Excellent | College             | surgery              | 40               | 0                  | 0                  | 0                  | 2                  | 4                  | 5                  | 5                  | 6                  | 6                  | 6                  |
| 05.30  | 3    | CBR        | M    | Male   | 58  | 157    | 73     | 28.53 | degree    | College             | surgery              | 30               | 0                  | 0                  | 0                  | 2                  | 4                  | 2                  | 2                  | 6                  | 6                  | 3                  |
| 05.30  | 5    | CBR        | F    | Female | 45  | 195    | 95     | 22.02 | degree    | College             | surgery              | 42               | 0                  | 0                  | 0                  | 2                  | 4                  | 7                  | 3                  | 5                  | 5                  | 6                  |
| 05.30  | 7    | CBR        | M    | Male   | 56  | 174    | 70     | 23.12 | degree    | Junior high      | surgery              | 26               | 0                  | 0                  | 0                  | 0                  | 4                  | 3                  | 1                  | 2                  | 4                  | 4                  |
| 05.30  | 9    | CBR        | M    | Male   | 63  | 147    | 69     | 22.99 | degree    | Higher school    | surgery              | 25               | 0                  | 0                  | 0                  | 0                  | 2                  | 3                  | 3                  | 3                  | 3                  | 3                  |
| 05.30  | 11   | CBR        | M    | Male   | 56  | 190    | 90     | 22.22 | degree    | Junior high      | surgery              | 34               | 0                  | 0                  | 0                  | 0                  | 2                  | 3                  | 3                  | 3                  | 4                  | 6                  |

*Note: VAS stands for Visual Analog Scale.*
| Year | ID | Gender | Age Start | Age End | Education | Occupation | Pain | Pain Severity | Treatment | Improvement | Side Effects | Decision |
|------|----|--------|-----------|---------|-----------|------------|------|--------------|-----------|-------------|-------------|----------|
| 2018 | 05-01 | 34 | M | 60 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-02 | 35 | CEB | M | 59 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-03 | 36 | CEB | M | 58 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-04 | 37 | CEB | M | 59 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-05 | 38 | CEB | M | 58 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-06 | 39 | CEB | M | 57 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-07 | 40 | CEB | M | 56 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-08 | 41 | CEB | M | 55 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-09 | 42 | CEB | M | 54 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-10 | 43 | CEB | M | 53 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-11 | 44 | CEB | M | 52 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-12 | 45 | CEB | M | 51 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-13 | 46 | CEB | M | 50 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-14 | 47 | CEB | M | 49 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-15 | 48 | CEB | M | 48 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-16 | 49 | CEB | M | 47 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-17 | 50 | CEB | M | 46 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-18 | 51 | CEB | M | 45 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| 2018 | 05-19 | 52 | CEB | M | 44 | 75 | Postgraduate | Excellent | 39 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 3 | 3 | No | 1 | 1 | 1 | 0 |
| Year | CEB | School | Gender | Grade | Exercise | Sleep | Nausea | Other | Pain | Presence | Other | Notes |
|------|-----|--------|--------|-------|----------|-------|--------|-------|------|----------|-------|-------|
| 2020 | 06/06 | PG | F | 38 | 143 | 33 | (5.6) | Excellent | 40 | 45 | 8 | 0 | 0 | 4 | 4 | 3 | 3 | 2 | 2 | 1 | 3 | 1 | 1 | 3 | 0 | Nausea: Yes, Normal sleep

Note: (T) indicates Nausea, (P) indicates Presence, (M) indicates Migraine.
| Year | Month | CEB | PCIA | Education | School | Operation | Description |
|------|-------|-----|------|-----------|--------|-----------|-------------|
| 2018-07-27 | 27 CEB | PCIA | 53 | 180 | 25 | 21.85486 | Unintended | Eventful | 50 | 78 | 30 | 1 | 0 | 2 | 4 | 0 | 3 | 5 | 3 | 3 | 3 | 1 | Yes | 2 | 1 | 0 | 5 |
| 2018-08-04 | 54 CEB | PCIA | 35 | 183 | 58 | 21.48006 | Unintended | Eventful | 48 | 49 | 30 | 0 | 0 | 0 | 0 | 4 | 2 | 0 | 0 | 3 | 3 | 2 | 3 | 4 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | Yes | 3 | 3 | 3 | 6 | 0 |
| 2018-08-07 | 37 CEB | PCIA | 51 | 175 | 60 | 30 | 61756 | Unintended | Eventful | 35 | 75 | 30 | 0 | 0 | 0 | 0 | 3 | 3 | 2 | 3 | 3 | 2 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | Yes | 3 | 3 | 6 | 0 |
| 2018-08-10 | 77 CEB | PCIA | 59 | 194 | 48 | 23.23848 | Unintended | Eventful | 20 | 65 | 30 | 1 | 0 | 0 | 2 | 4 | 2 | 0 | 0 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 2 | 3 | Yes | 3 | 3 | 6 | 0 |
| 2018-08-13 | 41 CEB | PCIA | 50 | 180 | 53 | 19.82588 | Unintended | Eventful | 20 | 60 | 30 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 5 | 2 | 3 | 5 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | Yes | 3 | 3 | 6 | 0 |
| 2018-08-16 | 82 CEB | PCIA | 53 | 187 | 72 | 29.63366 | Unintended | Eventful | 23 | 91 | 29 | 1 | 0 | 0 | 0 | 3 | 3 | 0 | 0 | 2 | 0 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | Yes | 3 | 3 | 6 | 0 |

If hours after the operation the patient had pain and discomfort in the anal area or back, and asked to pull out the analgesic pump and pull it next.
| Date       | Code | Type | Education Level | Admission | Year | Yes/No | Pruritus, Nausea |
|------------|------|------|-----------------|-----------|------|--------|------------------|
| 2020-07-24 | 99   | CIB  | Junior high     | Excellent | 20   | 20     | No               |
| 2020-07-27 | 90   | CIB  | Junior high     | Excellent | 18   | 48     | Yes              |
| 2020-07-29 | 91   | CIB  | Junior high     | Excellent | 20   | 0      | No               |
| 2020-07-31 | 92   | CIB  | Primary school  | Excellent | 29   | 162    | No               |
| 2020-08-03 | 93   | CIB  | Undergraduate   | Excellent | 15   | 60     | No               |
| 2020-08-05 | 94   | GA   | Master           | Pain      | 24   | 84     | No               |
| 2020-08-10 | 95   | CIB  | Undergraduate   | Excellent | 145  | 195    | No               |
| 2020-08-10 | 96   | CIB  | Junior high     | Excellent | 40   | 165    | Yes              |
| 2020-08-12 | 97   | CIB  | Junior high     | Excellent | 40   | 165    | Yes              |
| 2020-08-14 | 99   | CIB  | Undergraduate   | Excellent | 48   | 195    | No               |
| 2020-08-17 | 95   | CIB  | Junior high     | Excellent | 38   | 195    | No               |